AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04912219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedling
Description: Skin will be pretreated with topical 15% lidocaine creaml for 20 minutes. Water-soaked gauze will then be used to remove the lidocaine gel. Treated skin will be cleaned with 70% ethyl alcohol, allowed to dry, and then treated with hyaluronic acid gel.~Manual traction will be applied to the skin of the treatment arm, and the SkinPen microneedle device with 0.5mm microneedles attached will be passed over the forearm skin in a cross-hatch pattern until an endpoint of fine pinpoint bleeding is achieved.~Manual pressure with sterile ice water compresses will be used until hemostasis is achieved.~This will be repeated for a total of four treatments one month apart
Study NCT06355167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bacopa monnieri
Description: Daily oral intake of Bacopa monnieri during 6 weeks
Study NCT04685668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The PartoMa guidelines and training
Description: All health care providers (physicians and nurse-midwives) working at the Department of Obstetrics in five study sites during the study period will be invited to participate in knowledge tests of obstetric care and qualitative participant observations as well as in-depth interviews regarding quality of care. This is a part of evaluating the use and effectiveness of the PartoMa intervention.~The intervention includes the following two components:~1. Implementation of a pocket booklet with simple and locally achievable clinical guidance for safe and respectful care at birth developed by the research team and birth attendants at the five hospital study sites;~2. Quarterly, the birth attendants will be offered training in the use of the booklet in 3-hour case-based seminars.
Study NCT06528795 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scenario-based high-reality hybrid simulation method
Description: Intervention group students will be practiced with the Lactation Simulator, a high-reality simulator, in the simulation laboratory, accompanied by a scenario.
Study NCT04723563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: 25,000 units of unfractionated heparin nebulized 4 times daily for the duration of hospitalization
Study NCT04723563 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: 5 mL of 0.9% sodium chloride nebulized 4 times daily for the duration of hospitalization
Study NCT05020418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chart Review
Description: Intervention sites will receive a multi-faceted implementation intervention, which will include external and internal blended facilitation, education materials for providers and patients, and audit and feedback about practices and outcomes with benchmarking to non-intervention sites.
Study NCT05521841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block(Bilateral Ultrasound Guided Erector Spinae Plane Block)
Description: Bilateral USG guided Erector Spinae Plane Block:~Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg Ultrasound transducer will be placed in a cephalocaudal orientation over the back at 10th thoracic vertebral level.~The probe will then slowly be moved laterally until the transverse process is visible The trapezius muscle and erector spinae muscle will be identified as superficial to the transverse process.~A 25-gauge Quincke spinal needle (Romsons spinal needle, Quincke type)will be inserted using an in-plane approach in the cephalad to the caudal direction and towards the transverse process.~A 5ml bolus of local anesthetic will be given. Erector spinae muscle plane is then visualized separating from the transverse process.~The local anesthetic is then injected in 5 ml increments, with aspiration after every 5 ml to avoid intravascular injection Same procedure will be repeated on the other side
Study NCT05521841 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block(Bilateral Ultrasound-guided bilateral Transversus abdominis plane block)
Description: Bilateral Ultrasound-guided bilateral Transversus abdominis plane block Drug used 20 ml of 0.25% Bupivacaine in each side. Total 40 ml volume. Dosage 100mg The linear transducer will be placed in the transverse plane at the lateral abdominal wall in the mid-axillary line, between the lower costal margin and the iliac crest.~Abdominal wall muscles (external oblique, internal oblique, and transversus abdominis) will be visualized.~Bowel movement and visualization of hypoechoic peritoneum would further guide the block.~The needle will be inserted in-plane and advanced until the tip is between the internal oblique and the transversus abdominis muscle.~After negative aspiration, 20 mL of 0.25% bupivacaine is injected in a 5ml increment ,aspirating after every 5ml injection.~Same procedure will be repeated on the other side.
Study NCT06016439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff partial repair with superior capsular augmentation with LHBBT
Description: Residual rotator cuff defect will be reconstructed using LHBBT.
Study NCT06016439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff partial repair
Description: Rotator cuff will be repaired with remaining residual defect.
Study NCT06016439 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthroscopic complete rotator cuff repair
Description: Arthroscopic complete repair as a standard procedure.
Study NCT06016439 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture anchor(s)
Description: Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
Study NCT06016439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture anchor(s)
Description: Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
Study NCT06016439 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Suture anchor(s)
Description: Arthroscopic rotator cuff tendon(s) repair using suture anchor(s).
Study NCT06199349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMDTC for injection
Description: GMDTC for injection with a specification of 0.5g/vial, 500mg,1000mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Study NCT06199349 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial
Study NCT06367387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-Oriented Dosing (POD)
Description: Patient-oriented dosing (POD) is a promising approach to using buprenorphine or buprenorphine/naloxone to treat individuals with both OUD and chronic pain. It is based on existing evidence related to buprenorphine for the treatment of pain. POD allows participants to receive a daily dosage of bup up to 32mg/day, split up to 4 times per day.~A response-guided dosing strategy, in which buprenorphine or buprenorphine/naloxone doses will be titrated based on a participant response, will be used to identify a dose regimen that is safe and effective. Due to inter-individual pharmacokinetic/pharmacodynamic variability, POD dosing will be individualized based on a participant's pain intensity and interference.
Study NCT06367387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management (PSM)
Description: Pain self-management (PSM) is a manualized behavioral intervention consisting of 12 sessions, comprising 6 group and 6 individual sessions. The first session will be individual, followed by a group session, and then alternating weekly for the remainder of the intervention.~Individual sessions will be led by a staff Interventionist trained in the pain self-management intervention. The interventionist will guide participants through a PSM study manual, providing education, teaching associated skills, and assisting with goal setting.~Group sessions will be led by a Peer Facilitator who has experience with chronic pain, opioid use disorder, and buprenorphine treatment. These sessions will not have specific content but will serve as supportive forums for participants to discuss their experiences with the intervention, share tips for managing chronic pain, and provide mutual support.
Study NCT06367387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions.
Study NCT06367387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care, or treatment as usual, refers to the standard of care that participants receive at their office-based addiction treatment (OBAT) clinic. This includes discussing issues related to chronic pain and opioid use (e.g., buprenorphine) with their provider and receiving clinical care for these conditions.
Study NCT06367387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard Buprenorphine Dosing Condition
Description: Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
Study NCT06367387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Buprenorphine Dosing Condition
Description: Participants will continue standard buprenorphine or buprenorphine/naloxone dosing as part of normal clinical care.
Study NCT05071274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skinpen Prescision System
Description: Skinpen Precision is an automated nonsurgical micro needling device designed for use by licensed health care practitioners or individuals directed by practitioners. The device incorporates a sterile Microneedle cartridge and Biosheath for single use only.
Study NCT05126459 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Regimen 1
Description: Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5- 2mg/kg) + Meperidine (1.5 -2 mg/kg) + Midazolam (0.5- 0.75 mg/kg) In combination with oral drugs stated above, administeration via inhalation of Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
Study NCT05126459 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regimen #2
Description: Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Meperidine (1.5 -2 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
Study NCT05126459 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Regimen #3
Description: Administer orally after informed consent obtained prior to any dental procedure. Hydroxyzine (1.5 - 2mg/kg) + Midazolam (0.5- 0.75 mg/kg). Administer Nitrous oxide/oxygen (30-50% N2O/ 70-50% O2) via inhalation.
Study NCT05853757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zzowin Nutra Tablet
Description: 1 Tablet daily half an hour before going to bed
Study NCT05476991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Colchicine is a medication used to treat gout and Behçet's disease. In gout, it is less preferred to NSAIDs or steroids. Other uses for colchicine include the management of pericarditis and familial Mediterranean fever.
Study NCT05476991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90mg
Description: Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y 12 receptor.
Study NCT05476991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75-300mg
Description: Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
Study NCT05476991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 75-300mg
Description: Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI).
Study NCT06312995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: T3DDY01
Description: Digital acquisition of the patient's forearm using Intel RealSense D415 cameras (CE devices certified according to EN/IEC 60825-1 2007 - Safety of Laser product as Class I Laser Devices, i.e., Non-Hazardous Laser Radiation). The patient's arm is placed on a support to allow the plaster nurse to position the wrist at the correct angle needed to treat the fracture.
Study NCT06312995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLASTER
Description: Standard treatment plaster for fractures.
Study NCT05104879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biosketch Card
Description: The experimental group received a biosketch card during rooming, pre-clinician encounter that gave an overview of the midlevel providers qualifications.
Study NCT04587739 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Surgery with Neoadjuvant stereotactic body radiation therapy
Description: Stereotactic hypofractionated robotic radiation therapy (24-45 Gy / 3 fractions) followed after 4-6 weeks by conventional hepatectomy (either anatomical liver resection, or non-anatomical liver resection with intention to achieve a minimal 2 cm margin).
Study NCT04469959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Dopa
Description: Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days.
Study NCT04469959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Dopa
Description: Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days.
Study NCT04469959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
Study NCT04469959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.
Study NCT05547607 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: advanced cardiac imaging
Description: In all patients with high suspected or confirmed endocarditis at the echocardiography the following information will be collected: 1) endocarditis risk factors, 2) type, size and position of infected valve or prosthesis, 3) echocardiographic data; 4) imaging technique used for diagnosis in addition to echocardiography; 5) management of the case performed by the endocarditis team (including cardiologist, microbiologist, cardiac surgeon, radiologist); 6) Duke criteria verification; 7) management of the case (conservative or invasive); 8) antibiotic therapy prescribed and timing; 9) follow-up at one year (death, cardiac surgery, stroke, re-infection).
Study NCT05264519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: foot bath intervention
Description: Students in this group will have their feet soaked in water with a temperature of 38-42 degrees for 20 minutes, half an hour before bedtime.
Study NCT06649448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efbemalenograstim alfa Injection
Description: This product should be administered subcutaneously 48 hours after the completion of anti-tumor drug administration in each chemotherapy cycle. The recommended dose for adults is 20mg administered subcutaneously once per chemotherapy cycle. Please do not administer this product within 14 days before and 24 hours after the administration of cytotoxic chemotherapy drugs.
Study NCT06649448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin/cisplatin-etoposide
Description: one of the following chemotherapy regimens can be selected: EC, Q3W: Carboplatin AUC = 5\~6 on Day 1; Etoposide 80\~100 mg/m² on Days 1-3. EP, Q3W: Cisplatin 75\~80 mg/m² on Day 1; Etoposide 80\~100 mg/m² on Days 1-3.
Study NCT06649448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin plus Paclitaxel
Description: For non-small cell lung cancer (squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Carboplatin AUC = 5\~6 on Day 1 + Taxane: Paclitaxel 175-200 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, administered every 3 weeks (Q3W); Cisplatin/Carboplatin 75 mg/m²/AUC = 5\~6 on Day 1 + Gemcitabine 1000 mg/m² on Days 1 and 8, administered every 3 weeks (Q3W).
Study NCT06649448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/pemetrexed or Carboplatin/pemetrexed
Description: For non-small cell lung cancer (non-squamous cell carcinoma), one of the following chemotherapy regimens can be selected:~Cisplatin 75 mg/m² on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).~Carboplatin AUC = 5\~6 on Day 1 + Pemetrexed 500 mg/m² on Day 1, administered every 3 weeks (Q3W).
Study NCT06649448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP regimen
Description: The chemotherapy regimen options include:~TP regimen: Cisplatin 60-80 mg/m² administered via intravenous drip on Day 1 + Taxane: Paclitaxel 175 mg/m² on Day 1; or Albumin-bound Paclitaxel 200-260 mg/m² on Day 1, with a treatment cycle of every 3 weeks (Q3W).
Study NCT06657170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmunary veins reconnection plus hidden slow conduction ablation
Description: Ablation of pulmonary veins reconnections plus the search and ablation of hidden slow conductions sites (HSC) in the left atrium.~HSC sites are defined as EGMs showing highly fragmented or double electrograms in response atrial triple extrastimulus, presenting normal or fractionated electrogram in the sinus rhythm.~After checking for PV's conduction breakthroughs, point-by point ablation targeting HSC-EGMs will be performed.~The end point for HSC+ ablation will be reached with loss of local capture at a given lesion, pacing from the ablation catheter at high output (10V·2ms).
Study NCT06657170 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmunary veins (PV) reconnection ablation only
Description: Each vein will be re-assessed by observing PV potentials along the PV ostia and by pacing from the distal bipole of the ablation catheter (10mA at 2ms) within the lesion set with failed capture of the left atrium. In case of PVs reconnection touch-up applications will be performed at the earliest potential site, identified by comparing far-field atrial EGM to near-field local EGM timing, until isolation will be achieved (entrance and exit block).
Study NCT06620822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is the worlds first PD-1/IL-2α bispecific antibody fusion protein with an IL-2 arm that has been designed and modified to retain CD25 (IL-2Rɑ) activity to maximize efficacy and high selectivity, and to reduce binding to IL-2Rβγ to reduce systemic toxicity, whereas the PD-1 binding arm allows for blockade of PD-1 and selective delivery of IL-2. Therefore, IBI363 has the ability to simultaneously block the PD-1/PD-L1 pathway and activate the IL-2 pathway, which can more effectively activate tumor-specific T cells. IL-2, as an important cytokine for activating tumor-specific CD8+ T cells, is mechanistically complementary to immune checkpoint inhibitors, and can reverse T-cell depletion, thereby overcoming immune resistance.
Study NCT06620822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM-108+Sintilimab
Description: LM-108 is a humanized monoclonal antibody targeting the human chemokine CC receptor 8 (CCR8) and is able to modulate the tumor microenvironment by specifically removing tumor-infiltrating regulatory T cells (Treg) through antibody-dependent cell-mediated cytotoxicity (ADCC) without affecting peripheral Treg.